7 unchanged sentences
and AstraZeneca AB, dated as of October 20, 2014.
−Removed: Equity Distribution Agreement, dated August 8, 2022, among FibroGen, Inc.
+Added: Amended and Restated Equity Distribution Agreement by and between FibroGen, Inc.
and Goldman Sachs & Co.
+Added: LLC and BofA Securities, Inc., dated February 27, 2023.
+Added: Amendment No.
+Added: 1 to Commercial Supply Agreement (Roxadustat) by and between FibroGen, Inc.
+Added: and its Affiliates and Catalent Pharma Solutions, LLC dated as of January 1, 2023.
+Added: FibroGen, Inc.
+Added: Non-Employee Director Compensation Policy, as amended.
+Added: Form of Executive Officer Change in Control and Severance Agreement.
Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).
10 unchanged sentences
* Filed herewith
+Added: Portions of this exhibit (indicated by asterisks) have been omitted as the Company has determined that (i) the omitted information is not material and (ii) the omitted information would likely cause competitive harm if publicly disclosed or is the type of information the Company treats as confidential.
+Added: + Indicates a management contract or compensatory plan.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
FibroGen, Inc.
−Removed: November 7, 2022
/s/ Enrique Conterno
2 unchanged sentences
(Principal Executive Officer)
−Removed: November 7, 2022
/s/ Juan Graham
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.